Last reviewed · How we verify
NCT06764992
Exploring Men s Prostate Cancer Genetic Risk Perceptions
trial testing Questionnaire in Prostate Cancer in 100 participants. Completed in 7 June 2024.
20 April 2024
Quick facts
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 25 August 2022 |
| Primary completion | 20 April 2024 |
| Estimated completion | 7 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Questionnaire
- Saliva Sample — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Who can join
40 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The exploring men's prostate cancer genetic risk perceptions and willingness to give a biospecimen for genetic risk testing study aims to assess prostate cancer genetic risk and susceptibility beliefs among unaffected men of diverse races/ethnicities who are considering undergoing prostate cancer screening and their willingness of men to provide a biospecimen (saliva sample) and test the samples for prostate cancer aggressiveness and determine risk category based on SNP genetic profile.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Feasibility of Recruitment, Perceived Genetic Risk and Susceptibility Beliefs, and Saliva Sample Collection in a Community-Based Prostate Cancer Genetic Risk Pilot Study.
Boxtha C, El-Kolalli S, Denis J, O'Neil A, et al · · 2026 · PMID 41506624 · DOI 10.1177/15579883251410526
Verify or expand the search:
- PubMed search for NCT06764992
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire
Trials testing the same drug.
- NCT04466371 — Perceptions of Undergraduate Students and Teaching Staff on Online Teaching · suspended
- NCT07089953 — Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomiz · NA · not yet recruiting
- NCT07418775 — Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma · not yet recruiting
- NCT07226804 — Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules · not yet recruiting
- NCT07532954 — The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support · recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other H. Lee Moffitt Cancer Center and Research Institute trials
Trials by the same sponsor.
- NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
- NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
- NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
- NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
- NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06764992 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06764992.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing